Beam Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit
20 oct. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Preclinical Data Highlighting Base Editing Approach to Correct a Glycogen Storage Disease Type Ia Disease-Causing Mutation
19 oct. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new...
Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeting CD5 at 2021 SITC Annual Meeting
01 oct. 2021 08h44 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
28 sept. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Preclinical Data Highlighting Potential of Base Editors to Target Disease Drivers of Chronic Hepatitis B Infection
27 sept. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced...
Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues
23 sept. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new...
Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
08 sept. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results
10 août 2021 06h30 HE
|
Beam Therapeutics
Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of IND-Enabling Studies for BEAM-201 CAMBRIDGE,...
Beam Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
03 août 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the 2021 William Blair Biotech Focus Conference
08 juil. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...